IMIDs affect large populations across the globe, are chronic and costly conditions, and affect patients in the prime of their lives.
They constitute a broad class of diseases, including inflammatory bowel disease, multiple sclerosis, psoriatic arthritis, rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, in which dysregulation of the immune response leads to inflammatory pathophysiology and ultimately tissue destruction.
The collaboration will give Gossamer's world-class immunology research and development team the ability to benefit from IMIDomics' unique clinical and molecular patient database to ultimately inform product discovery and development strategy.
The agreement allows Gossamer to select and collaborate with IMIDomics on multiple projects, the first project being in the field of inflammatory bowel disease.
IMIDomics provides critical insights for treating patients with Immune-Mediated Inflammatory Diseases (IMIDs).
IMIDomics' comprehensive platform integrates access to a dynamic and high quality IMID patient biobank, corresponding curated clinical data, associated proprietary multiomics molecular data and world-class clinical expertise.
The company's analytics platform extracts unique insights into disease biology and patient conditions through our proprietary interactive portal. IMIDomics' unique capabilities result in novel insights that drive drug discovery and development, and guide precision treatment of patients.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007